A Study of Milvexian in Healthy Adult Females

Phase 1 Completed 20 enrolled Janssen Pharmaceutica N.V., Belgium Bristol Myers Squibb Company (BMS) · collab

NaSingle-groupOpen-labelOther

Summary

The purpose of this study is to measure the effect of milvexian given for approximately 2 weeks on (a) how the liver metabolizes other drugs (in this case one called midazolam), and (b) the pharmacokinetics (the way the body absorbs, distributes, and gets rid of a drug) of an oral contraceptive pill in healthy adult females.

Timeline

Start: 2023-01-25
Primary completion: 2023-07-20
Completion: 2023-07-20

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Midazolam	Small molecule	—	Oral
Subject	Milvexian	Small molecule	—	Oral
Subject	drospirenone	Unknown	—	Oral
Subject	ethinyl estradiol	Small molecule	—	Oral

Indications

No indication recorded.